FamiCord Group

Name

FamiCord Group

Legal name

FamiCord AG

Website

https://famicord.eu

Company type

Private

Founded year

2002

Operating status

Operating

Headcount range

101–250 employees

Ownership category

akta.pro rank

Product category

Stem Cell Banking and Cell Therapy Services

NAICS

Blood and Organ Banks (621991), Research and Development in Biotechnology (except Nanobiotechnology) (541714), Pharmaceutical Preparation Manufacturing (325412)

SIC

Biological Products, (No Disgnostic Substances) (2836), Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

Cell Therapy CDMO (HLAGABAD)

akta.pro secondary industry

Biologics (mAbs/Recombinant Proteins) CDMO (HLAGABAC)

Keywords

• Stem cell banking
• Cord blood storage
• Cell therapy CDMO
• Perinatal tissue preservation
• Cryogenic biological storage

Headquarters

HQ city

Warsaw

HQ country

Poland

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B and B2C

Offering type

Services

Cost components

Personnel, Operations, Technology or R&D, Infrastructure, Supply Chain, Marketing or Sales

Revenue model

1. Family Stem Cell Banking Services: Cord blood and tissue banking services for families, including collection, processing, testing, and long-term storage. Revenue is generated through initial banking fees and ongoing storage fees.
2. CDMO Services for Biotech and Pharma: Contract development and manufacturing organization services for biotech companies and clinics developing cell-based therapies. Includes process development, tech transfer, cGMP manufacturing, and analytics.
3. Expanded Access Programme: Clinical application services providing stem cell therapies to patients through controlled access programs, bridging research to real-world application.

Go-to-market motion2 records

Distribution channels3 records

Marketing channels3 records

Core offering

FamiCord Group is Europe's leading stem cell bank, collecting, processing, testing, and cryogenically storing umbilical cord blood, cord tissue, and placenta tissue for families. The company also operates as a Contract Development and Manufacturing Organization (CDMO) for biotech companies and clinics, providing process development, tech transfer, cGMP manufacturing, analytics, and global logistics for cell therapy Advanced Therapy Medicinal Products (ATIMPs).

Product overview

FamiCord Group operates as Europe's leading stem cell bank, offering a portfolio of cell banking services centered on preserving perinatal cells and tissues. The core family-focused offering includes Stem Cells Banking (umbilical cord blood and tissue collection and storage) and Stem Cells preservation services. The company also provides an Expanded Access Programme for patients seeking experimental cell therapies outside clinical trials. For biotech companies and clinics, FamiCord offers CDMO services for cell therapy ATIMPs, encompassing process development, cGMP manufacturing, and global logistics. The portfolio spans family banking services and business-to-business contract manufacturing services.

Differentiator

Problem solved

Functional benefit

Brands

• PBKM: Stem cell bank brand, evidenced by logo on website and partnership with pbkm.pl in Poland

Products and services

• Stem Cells Banking Collection and long-term cryogenic storage of umbilical cord blood and cord tissue for families, intended for potential future medical treatments and therapies.
• Stem Cells Preservation Preservation services for perinatal cells and tissues, including umbilical cord blood, cord tissue, and placenta tissue, offered to expectant parents and families.
• Expanded Access Programme Program providing access to stem cell therapies for patients outside of standard clinical trials, including therapies for conditions such as autism spectrum disorder.
• CDMO Services for Business Partners Contract Development and Manufacturing Organization services for cell therapy ATIMPs, including process development and optimization, tech transfer, cGMP manufacturing, cell/tissue sourcing, analytics, and global logistics, offered to biotech companies, pharmaceutical firms, and clinics.
• Stem Cells Banking for Society Stem cell banking services focused on societal benefit and accessibility for broader populations beyond standard family banking offerings.

Quantifiable outcome

• Over 260 cord blood transplantations or infusions enabled
• +2 more outcomes

Segments3 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Scale indicators6 records

Recent moves6 records

Expansion highlights5 records

Direct peers

• Vita34 AG: Vita34 is a leading German/Austrian stem cell bank offering umbilical cord blood and tissue storage services, and a direct competitor in FamiCord's home German-speaking market; it also appears as a partner/regional brand on FamiCord's homepage.
• Cryo-Cell International: Cryo-Cell is one of the largest private family cord blood banks globally, offering a directly comparable consumer cord blood and tissue banking service with subscription-based storage fees in overlapping model.
• ViaCord (Revvity): ViaCord is a US family cord blood and tissue bank (now part of Revvity/PerkinElmer) that competes head-to-head on the same consumer-preservation value proposition and storage-economics model as FamiCord.
• Cord Blood Registry (CBR): CBR is among the largest US family cord blood banks, offering nearly identical services (collection kit, processing, long-term storage) and serving the same consumer segment as FamiCord's family banking business.
• Crioestaminal: Crioestaminal is a Portuguese family cord blood bank referenced as a FamiCord regional partner on the homepage, operating the same consumer stem cell banking model in Iberia.
• Biogenis: Biogenis is a Romanian stem cell bank listed as a FamiCord regional partner in Romania, offering a near-identical family cord blood banking proposition and competing within a shared network.
• Cellaviva: Cellaviva is a Scandinavian family stem cell bank listed as a FamiCord partner on the homepage, providing directly comparable cord blood and tissue storage services in Sweden and Denmark.

Broad incumbents

• Lonza Group: Lonza is a global CDMO with a sizable cell and gene therapy services franchise that overlaps with FamiCord's CDMO ATIMP offering; broader portfolio but directly competes for biotech cell therapy manufacturing contracts.
• Catalent: Catalent is a large CDMO with cell therapy capabilities (Paragon) that competes for similar biotech development and manufacturing engagements as FamiCord's business-to-business arm.
• Charles River Laboratories: Charles River provides cell and gene therapy CDMO services including process development and cGMP manufacturing, overlapping with the manufacturing services FamiCord offers biotech clients.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/polish-stem-cells-bank-pbkm-

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about FamiCord Group